Therapy Areas: Inflammatory Diseases
Upsher-Smith launches generic Cyclosporine Ophthalmic Emulsion 0.05%
21 May 2026 - Upsher-Smith Laboratories LLC, a subsidiary of Bora Pharmaceuticals Co Ltd (TW:6472 and OTCQX:BORAY), announced on Wednesday that it has launched its Cyclosporine Ophthalmic Emulsion 0.0...
Accro Bioscience completes USD50m Series C financing
19 May 2026 - Clinical-stage biotechnology company Accro Bioscience Inc announced on Monday the closing of its USD50m Series C financing.The round was led by OrbiMed, with participation from TCG Cross...
Atisama Therapeutics reports progress in Phase 1 study of RB042
18 May 2026 - Atisama Therapeutics (formerly Rage Bio), an Australian clinical-stage biotechnology company, on Friday reported progress in the Phase 1 study of its lead candidate, RB042.The RB042 Phas...
Mabwell's clinical trial application for 9MW5211 cleared by US FDA
11 May 2026 - Chinese biopharmaceutical company Mabwell (SH:688062) (HK:02493) announced on Friday that the Investigational New Drug (IND) application for 9MW5211, its independently developed novel an...
Specialised Therapeutics' chronic graft-versus-host disease therapy approved in Australia
4 May 2026 - Australia-based independent biopharmaceutical company Specialised Therapeutics (ST) announced on Sunday that its NIKTIMVO (axatilimab) has been approved for use in Australia by the Therap...
Insilico's Rentosertib inhalation solution receives IND clearance to enter direct-to-lung clinical study
29 April 2026 - Insilico Medicine (HKEX:3696), a China-based, clinical-stage, generative AI-driven drug discovery company, announced on Tuesday that the inhalation solution of Rentosertib (ISM001-055)...